Roche deepens China biotech ties with Defand discovery deal

Roche is moving beyond licensing to a broader discovery partnership with Chinese biotech Defand Therapeutics, signaling deeper integration of Chinese R&D into Western pharma pipelines. The deal's financial terms and specific targets are undisclosed, and its impact on drug development timelines remains uncertain. This reflects a trend of Western pharma leveraging Chinese innovation amid geopolitical tensions.